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RESEARCH ARTICLE

Open Access

High-risk human papillomavirus (HPV) screening
and detection in healthy patient saliva samples:
a pilot study
Deidre O Turner1, Shelley J Williams-Cocks2, Ryan Bullen3, Jeremy Catmull3, Jesse Falk3, Daniel Martin3,
Jarom Mauer3, Annabel E Barber2, Robert C Wang2, Shawn L Gerstenberger1 and Karl Kingsley3*

Abstract
Background: The human papillomaviruses (HPV) are a large family of non-enveloped DNA viruses, mainly
associated with cervical cancers. Recent epidemiologic evidence has suggested that HPV may be an independent
risk factor for oropharyngeal cancers. Evidence now suggests HPV may modulate the malignancy process in some
tobacco- and alcohol-induced oropharynx tumors, but might also be the primary oncogenic factor for inducing
carcinogenesis among some non-smokers. More evidence, however, is needed regarding oral HPV prevalence
among healthy adults to estimate risk. The goal of this study was to perform an HPV screening of normal healthy
adults to assess oral HPV prevalence.
Methods: Healthy adult patients at a US dental school were selected to participate in this pilot study. DNA was
isolated from saliva samples and screened for high-risk HPV strains HPV16 and HPV18 and further processed using
qPCR for quantification and to confirm analytical sensitivity and specificity.
Results: Chi-square analysis revealed the patient sample was representative of the general clinic population with
respect to gender, race and age (p < 0.05). Four patient samples were found to harbor HPV16 DNA, representing
2.6% of the total (n = 151). Three of the four HPV16-positive samples were from patients under 65 years of age
and all four were female and Hispanic (non-White). No samples tested positive for HPV18.
Conclusions: The successful recruitment and screening of healthy adult patients revealed HPV16, but not HPV18,
was present in a small subset. These results provide new information about oral HPV status, which may help to
contextualize results from other studies that demonstrate oral cancer rates have risen in the US among both
females and minorities and in some geographic areas that are not solely explained by rates of tobacco and alcohol
use. The results of this study may be of significant value to further our understanding of oral health and disease
risk, as well as to help design future studies exploring the role of other factors that influence oral HPV exposure, as
well as the short- and long-term consequences of oral HPV infection.

Background
The human papillomavirus (HPV) has been implicated
as the cause of virtually all cervical cancers worldwide
[1-3]. These represent a large family of non-enveloped
DNA viruses that may be found integrated into the host
genome, non-integrated or episomal, or as a combination or mixture of these types in infected tissues [4-9].
* Correspondence: karl.kingsley@unlv.edu
3
University of Nevada, Las Vegas - School of Dental Medicine, Department of
Biomedical Sciences, Las Vegas, Nevada, USA
Full list of author information is available at the end of the article

HPV viruses infect many types of epithelial cells, with
intraepithelial neoplasias accounting for the overwhelming majority of HPV-related cancers [5,10,11].
Recent epidemiologic evidence has suggested that
HPV may also be an independent risk factor for oropharyngeal cancer, revealing HPV in three times as
many pre-cancerous oral lesions, and almost five times
as many oropharyngeal cancers compared with normal
oral mucosa [12-14]. Of all HPV types, the high-risk
strains HPV16, and to a lesser extent HPV18, are most
commonly identified from oral biopsies [15-21].

© 2011 Turner et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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Although the traditional risk factors for developing oropharyngeal cancer remain tobacco use and heavy alcohol
consumption, other risk factors, such as HPV, may play
significant roles in determining whether it develops and
how quickly it may progress [14,19,22-28].
The comparatively low presence of high-risk HPV in
normal tissues and much higher prevalence in pre-cancerous and cancerous oropharyngeal lesions may suggest
that HPV preferentially infects already developing oropharyngeal cancers [12-14]. Although it is possible that
the low prevalence in healthy individuals might be attributable to other factors, including improper specimen
collection or assay sensitivity, it is also possible that
HPV may function to modulate the malignancy process
in developing or established oropharyngeal tumors, as
has been observed in studies of HPV infection in other
developing cancers [29-39]. For example, recent epidemiologic and case-control studies have demonstrated
that patients with HPV-positive oropharyngeal tumors
had significantly improved survival rates [12,40,41] and
therapeutic response rates when compared with HPVnegative controls [42]. Several in vitro studies have
recently investigated possible mechanisms that may
account for these phenotypic changes in oropharyngeal
cancers [25-27]. Evidence is now accumulating that
HPV infection of some oropharyngeal cancers correlates
with increased survival rates and better prognosis
among some patients due to these changes in cellular
responsiveness [40-45]. These studies highlight the need
to understand not only the prevalence of oral HPV
infection, but also the duration and persistence of such
infections, due to their potential to affect oropharyngeal
tumor progression.
It is likely that HPV may modulate the malignancy
process in some tobacco- and alcohol-induced oropharyngeal cancers, but may also be the primary oncogenic
factor for inducing carcinogenesis in a subset of patients
without these traditional risk factors. Some evidence has
demonstrated that non-tobacco and non-alcohol related
oropharyngeal cancers were six times more likely to harbor HPV infections than case-matched controls [46]. To
accurately evaluate risk, more estimates of oral HPV
prevalence among healthy adults are needed. International studies have evaluated HPV prevalence in healthy
adults using biopsy samples, revealing prevalence rates
that ranged from 0 to 15% [20,47-51]. In addition, other
studies have begun to report less invasive saliva and oral
lavage-based testing methods to identify HPV among
healthy adult saliva samples, revealing prevalence rates
between 2.8 to 25% [15,52-60].
Some of these oral HPV screening studies were performed in the US on normal, healthy adults, in addition
to oropharyngeal cancer patients [57,58,61]. These studies have reported much lower rates, between 1.3 and

Page 2 of 8

7%, than in previous international studies [47,50,53].
Based upon this information, the goal of this project
was to perform a screening for the most prevalent highrisk HPV strains, HPV16 and HPV18, in normal healthy
adults. This pilot study was performed in Nevada, a
state recently documented to have increasing rates of
oropharyngeal cancer between 1997 and 2005 - despite
declining rates of tobacco and alcohol use in the state,
as well as declining rates of oropharyngeal cancer
nationally [23,24]. The long-term goal is to provide
more detailed information about high-risk oral HPV
prevalence to allow for more robust estimates of oropharyngeal cancer risk.

Methods
Human Subjects

The protocol for this study titled “The Prevalence of
Oral Human Papilloma Virus (HPV) in the University of
Nevada, Las Vegas - School of Dental Medicine (UNLVSDM) Clinic Population” was filed, amended, and
approved by the UNLV Office of Research Integrity Human Subjects (OPRS#1002-3361) on April 9, 2010. In
brief, subjects in this convenience sample were recruited
by members of the UNLV-SDM Clinic during their dental visit on one of 15 clinic dates. Informed Consent was
required and was conducted onsite. Inclusion criteria:
subjects had to be 18 years old or older and must agree
to participate. Exclusion criteria: subjects younger than
18 years of age, subjects that declined to participate, and
subjects with prior diagnosis of oropharyngeal cancer
were excluded.
Sample size

To determine an appropriate sample size, previous studies that screened for high-risk oral HPV in healthy
adults were evaluated to determine the range of sample
sizes, which varied greatly from 12 - 1,680 [47-62]. Previous research at UNLV and the UNLV-SDM clinic
demonstrated low participation rates for invasive, bloodbased screenings [63], but higher rates of participation
using non-invasive biomonitoring and screening methods, including saliva collection (unpublished data).
These studies had sample sizes ranging from 16 - 200.
Based upon this combined information the maximum
sample size was estimated to be 200.
Saliva Collection Protocol

In brief, healthy adults who agreed to participate were
given a small, sterile saliva collection container, a 50 mL
sterile polypropylene tube from Fisher Scientific (Fair
Lawn, NJ). Participants were then asked to chew on a
small piece of paraffin wax for one minute and then to
expectorate. Samples were stored on ice until transport
to a biomedical laboratory for analysis. Each saliva
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sample was assigned a unique, randomly-generated
number to prevent research bias. Demographic information regarding the sample was concurrently collected,
which consisted of age, gender, and ethnicity only.
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captured using a Kodak Gel Logic 100 Imaging System
and 1D Image Analysis Software (Eastman Kodak:
Rochester, NY).
Quantitative PCR (qPCR)

Cell counting and DNA isolation

All samples were centrifuged for 10 minutes at 2,100 g
(RCF) and the pellet washed with 1X phosphate-buffered saline (PBS) (HyClone: Logan, UT) and resuspended in 5 mL of 1X PBS. Cell number was
determined using Trypan Blue (Fisher Scientific: Fair
Lawn, NJ) using a Zeiss Axiovert 40 inverted microscope (Gottingen, Germany) and a hemacytometer
(Fisher Scientific: Fair Lawn, NJ). To determine if any
samples harbored the HPV virus, DNA was isolated
from the saliva sample using a minimum of 3.5 × 105
cells and the GenomicPrep DNA isolation kit (Amersham Biosciences: Buckinghamshire, UK), using the procedure recommended by the manufacturer, as previously
described [26,27,32]. DNA purity was calculated using
ratio measurements of absorbance at 260 and 280 nm
(A260/A280 ratio between 1.7 and 2.0).
Polymerase chain reaction (PCR)

DNA from each sample was then used to perform PCR
with the Fisher exACTGene complete PCR kit (Fisher
Scientific: Fair Lawn, NJ) and a Mastercycler gradient
thermocycler (Eppendorf: Hamburg, Germany) using the
following primers for HPV16 [26,27], HPV18 [27,32],
and glyceraldehyde- 3- phosphate dehydrogenase
(GAPDH) [64], synthesized by SeqWright (Houston,
TX):
HPV16
forward
primer,
ATGTTTCAGGACCCACAGGA;
HPV16
reverse
primer,
CCTCACGTCGCAGTAACTGT;
HPV18
forward
primer,
ATGGCGCGCTTTGAGGATCC;
HPV18
reverse
primer,
GCATGCGGTATACTGTCTCT;
GAPDH
forward
primer,
ATCTTCCAGGAGCGAGATCC;
GAPDH
reverse
primer,
ACCACTGACACGTTGGCAGT;
One μg of template DNA was used for each reaction.
The initial denaturation step ran for three minutes at
94°C. A total of 30 amplification cycles were run, consisting of 30 second denaturation at 94°C, 60 seconds of
annealing at 58°C, and 30 seconds of extension at 72°C.
Final extension was run for five minutes at 72°C. The
PCR reaction products were separated by gel electrophoresis using Reliant 4% NuSieve ® 3:1 Plus Agarose
gels (Lonza: Rockland, ME). Bands were visualized by
UV illumination of ethidium-bromide-stained gels and

DNA samples were then processed using qPCR to provide more specific and sensitive quantification. Primers
and probes were designed using Roche Universal Probe
library (UPL) assay design software to amplify the region
overlapping E6 and E7 gene sequence of HPV16 [GenBank: K02718] and the human b-actin housekeeping
gene [GenBank: M10277]. All primers were purchased
from Sigma-Aldrich (St. Louis, MO.) and probes purchased from Roche Applied Science (Indianapolis, IN.)
HPV16 E6/E7 forward primer 5’-CAACTGATCTCTACTGTTATGAGCAA-3’, HPV16 E6/E7 reverse primer 5’-CCAGCTGGACCATCTATTTCA-3’, HPV16 E6/
E7 hydrolysis “Taqman” probe 5’-(fam)-AGGAGGAG(dark quencher dye)-3’ (UPL probe #63) was used to
amplify the 73 base pair (bp) region between the 535
nucelotide (nt) position and 607 nt position. Human bactin forward primer 5’-GTGGGGTCCTGTGGTGTG3’, human b-actin 5’-GAAGGGGACAGGCAGTGA-3’,
human b-actin hydrolysis “Taqman” probe 5’-(fam)GGGAGCTG-(dark quencher dye)-3’ (UPL probe #24)
amplified the 61 bp region between 2642 nt position
and 2702 nt position.
The real-time reaction mixture was prepared in a
LightCycler ® 480 multiwell Plate 96 containing 1×
LightCycler ® 480 Probes Master (Roche Applied
Sciences), 1 μM of each respective primer set (forward
and reverse), 0.2 μM of respective probe, and 2 μl of
DNA template; in a 20 μl final reaction volume. The
probes master mix contained reaction buffer, dNTP mix
(including dUTP in place of dTTP), 3.2 mM MgCl2, and
Taq DNA polymerase. The real-time PCR assay was
performed on a LightCycler 480 system (Roche Applied
Science) with the following cycle parameters: pre-incubation for initial enzyme activation at 95°C for 10 minutes, followed by 45 cycles of 95°C for 10 seconds (ramp
rate 4.4°C/second), 60°C for 30 seconds (ramp rate 2.2°
C/second) and 72°C for 1 second (ramp rate 4.4°C/second). Following amplification phase, a cooling step was
performed at 40°C for 30 seconds (ramp rate of 2.2°C/
second). Acquisition of the fluorescence signal was performed using Mono Hydrolysis Probe setting (465-510
nm) following the 72°C extension phase of each cycle.
All samples were carried out in triplicate.
Analytic sensitivity

The CaSki (American Type Culture Collection; Manassas, VA) cervical adenocarcinoma cell line was used to
develop standard curves for both the HPV16 (600
copies/genome) and b-actin (2 copies/genome) genes.

Turner et al. BMC Oral Health 2011, 11:28
http://www.biomedcentral.com/1472-6831/11/28

Page 4 of 8

DNA extracted from CaSki cells was serially diluted tenfold starting at 50 ng to 0.0005 ng [65]. This step
allowed for relative quantification of the input DNA
level and final quantity as the number of viral copies/
genome/cell. Quantification was achieved using Cycle
Threshold (C T ) measured with the second derivative
maximum method (LightCycler 480 Software version
1.5.0.39; Roche Applied Science). Saliva samples > 0.001
copy/genome were considered HPV positive. Specificity
analysis was performed on qPCR assay against HPV18
and found to be 100% specific (data not shown).
Statistical evaluation

Sensitivity and specificity were calculated as the proportion of true positives and true negatives (cutoff value >
0.001 copies/genome), respectively. Following the acquisition of saliva samples and HPV screening results,
demographic information from each sample was compared with the overall demographic profile of the
UNLV-SDM patient pool (N = 71, 051) using a chisquare (c2) test, to determine if any characteristic (gender, race, age) was different than expected among the
patients evaluated in this study (n = 151). A probability
level of alpha (a) = 0.05 was used to determine statistical significance.

Results
Samples of saliva were collected from 151 UNLV-SDM
patients between June 2 and October 1, 2010. The
patients from whom samples were collected and
screened were not statistically different from the overall
UNLV-SDM clinic population with respect to gender,
race, or age (Table 1). More specifically, the total number of females and males in the sample was roughly
equal (52.3% and 47.7%, respectively) and not significantly different than the overall clinic population (p =
0.589). There were slightly more White patients in the
study sample (48.3%) than in the overall UNLV-SDM
population (40.8%) (p = 0.133). In addition, there were
slightly fewer 18 - 64 year olds in the sample (80.8%)
than in the overall clinic (85.3%) (p = 0.354).
Table 1 Demographic analysis of study participants
Variables

UNLV-SDM

Study sample

Statistical analysis

n = 35,952 (50.6%) n = 79 (52.3%)
n = 35,099 (49.4%) n = 72 (47.7%)

c2 = 0.119, d.f. = 1
p = 0.589

White

n = 28,989 (40.8%) n = 73 (48.3%)

c2 = 1.621, d.f. = 1

Non-White

n = 42,062 (59.2%) n = 78 (51.7%)

p = 0.133

Gender
Female
Male
Race

Age
18 - 64 years n = 60,598 (85.3%) n = 122 (80.8%) c2 = 1.056, d.f. = 1
65 +

n = 10,453 (14.7%) n = 29 (19.2%)

p = 0.354

Analysis of saliva samples revealed cell counts varying
between 0.8 - 2.4 × 106 cells/mL (Table 2). DNA was
successfully isolated from all collected saliva samples,
with average DNA concentrations ranging between 820
- 1047 ng/μL. Absorbance measurements and A260/
A280 ratio analysis confirmed the purity of the DNA
isolates, which averaged between 1.87 and 2.05.
The extracted DNA was subsequently screened for the
presence of HPV16 and HPV18 using PCR (Figure 1).
From this screening, four patient samples were determined to be HPV- positive, which represented 2.6% of
the total screened (n = 4/151). All four samples harbored HPV16 DNA and none were found to be positive
for HPV18. Although a positive sample pool of only
four patients does not allow for any broader inferences
or conclusions, a preliminary descriptive analysis of
demographic information revealed these four samples
were from females, who were also minority (non-White,
Hispanic) (Table 3). Three of the four samples were
from patients between 18 - 64 years of age (2.0%), and
one sample came from a patient over 65 years of age
(0.7%).
DNA samples were then processed using quantitative
qPCR to provide quantitative assessment, as well as
measurement of sensitivity and specificity (Figure 2).
Analysis of the range of copy number/genome for the
housekeeping gene (b-actin) within HPV-negative
(range: 4 - 363 copies/genome) and HPV-positive samples (range: 75-1096) were similar and well above the
cutoff value (> 0.1 copies/genome). Analysis of qPCR
results in copy number/genome for HPV revealed striking differences in copy numbers between HPV-negative
(range: 0.0001 - 0.000004 copies/genome) and HPVpositive (range: 70 - 111), which were easily distinguished using the cutoff value (> 0.001 copies/genome).
No false positives or false negatives were found, demonstrating sufficient sensitivity and specificity to ascertain
the proportion of true positives (4/4 or 100%) and true
negatives (147/151 or 100%).

Discussion
The primary aim of this study was to perform an oral
screening of normal healthy adults in Nevada for highrisk HPV. Previous attempts at this institution and
within the state to obtain blood-based samples for other
types of screenings, such as lead (Pb) levels, have been
largely unsuccessful due to patient apprehension and
fear of blood collection [63]. To avoid these specific
problems, this study utilized non-invasively collected saliva to perform this analysis. These efforts ultimately
allowed for the collection and screening of dozens of
patient samples; a marked improvement in patient participation rates over other previous, but similar, attempts
to collect biological specimens from the local

Turner et al. BMC Oral Health 2011, 11:28
http://www.biomedcentral.com/1472-6831/11/28

Page 5 of 8

Table 2 Cell count and DNA isolation
Cell count (cells/mL)

Average DNA concentration (ng/μL)

A260/A280

Samples (n)

0.8 - 1.2 × 106

915

2.05

31

1.6- 1.9 × 106

820

1.87

94

2.1 - 2.4 × 106

1047

1.95

26

S: 2430

S: 2527

S: 2718

S: 2819

GAPDH
HPV18
HPV16

(+) control

population. The results of this current study provide
new data from a previously unscreened patient population and geographic area to complement the growing
corpus of information about oral HPV prevalence
among healthy adults.
These data demonstrated a prevalence rate of highrisk oral HPV (2.6%) virtually the same as the most
recent multinational studies of healthy, cancer-free
adults (3.1% to 5%) [61,62]. Over the past few decades,
international studies have evaluated HPV prevalence in
healthy adults using biopsy samples, which reported
widely variable prevalence rates that ranged from 0 15% [47-51]. However, other recently published reports
screening for oral HPV infection among healthy adults
using saliva and oral lavage testing reported overall prevalence rates that were also close to this range (1.3%,
2.8%, 7%) [52-59].
In addition, although the results of this study found
oral HPV infection only among four patients, who were
minority and female, the vast majority of female and
minority patients in this study had no evidence of oral
HPV infection. As an initial pilot study, these data suggest a more comprehensive and in-depth analysis of this
population may be necessary, as recent epidemiologic
studies have shown that rates of oropharyngeal cancer
haven risen sharply among minority females in the US,
despite overall declining rates [66]. More generally, rates
of oropharyngeal cancer have risen among some minority subgroups [67], despite an overall decline among the
general population in the US [23,24,68]. This may be
explained, in part, by higher rates of tobacco and

Figure 1 Screening of patient samples for HPV. PCR using DNA
extracted from patient samples (n = 151) was screened using
HPV16- and HPV18-specific primers, which revealed four samples
harbored HPV16 (2819, 2718, 2527, and 2430). No samples were
found to harbor HPV18. DNA extracted previously from cervical
adenocarcinoma cell lines, CaSki and GH354, was used as HPV16
and HPV18 positive controls, respectively.

alcohol use, but may also be attributable to other factors
including education, income, stress, diet, health literacy
and exposure to oral infectious agents [22,25]. This pilot
study provides preliminary information about oral HPV
prevalence and the results suggest that further investigation may be warranted, particularly in light of the health
disparities facing both females and minorities in Nevada
and the US, in general [23,24].
This study also revealed the presence of the high-risk
strain HPV16, but not HPV18. Although some reports
have suggested that oral HPV infection may involve
multiple HPV strains [15-21,69], this result is not dissimilar from other findings which suggest HPV16 may
account for the overwhelming majority of HPV-positive
oral samples [48,49,53,57,59]. It is likely that further
expansion of this project to include larger samples will
uncover additional HPV strains to provide more extensive estimates of oral HPV infection within this
population.
This study had several limitations that should be considered. First, although the non-invasive nature of this
study was sufficient for the recruitment and screening of
a significant number of patients, the overall sample size
was somewhat limited in comparison to the larger multinational studies previously mentioned [57,58,61]. The
number of healthy adults screened for oral HPV in this
pilot study, however, compares favorably with a number
of other reports - with sample sizes ranging from 12 to
97 [20,47-53]. Second, detailed demographic and behavioral data were not designated as critical to the initial
goals of this pilot study, however, the inclusion of smoking and tobacco use, as well as more detailed information about other behaviors, housing, education, income
and other socioeconomic indicators, as well as sexual
Table 3 Analysis of HPVscreening
Variables

HPV16-positive

HPV18-positive

HPV-negative

n = 4 (2.6%)
n=0

n=0
n=0

n = 75 (49.7%)
n = 72 (47.7%)

White

n=0

n=0

n = 73 (48.3%)

Non-White

n = 4 (2.6%)

n=0

n = 74 (49.0%)

18 - 64 years

n = 3 (2.0%)

n=0

n = 119 (78.8%)

65 +

n = 1 (0.7%)

n=0

n = 28 (18.5%)

Gender
Female
Male
Race

Age
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10000

Copy number / genome

1000

-actin HPV16 HPV18

-actin HPV16

HPV18

100
10
1

0.1
0.01
0.001

0.0001
0.00001

HPV-positive samples
-actin
(copies/genome)

HPV-negative samples

HPV16
HPV18
(copies/genome) (copies/genome)

195
75
1096
751

70
111
87
96

0.00001
0.0005
0.00039
0.0007

Range:
4 – 363

Range:
0.0001 - .000015

Range:
0.001 – 0.000004

Sample ID

HPV-positive
2527
2430
2819
2718
HPV-negative
n = 147

Figure 2 Graphic analysis of qPCR HPV screening results. Plotting of copy number/genome for housekeeping gene (b-actin) was similar
from samples of HPV-positive (range: 75-1096) and HPV-negative samples (range: 4 - 363 copies/genome). Copy number/genome using qPCR
was significantly above the cutoff value (> 0.1 copies/genome), confirming the HPV-positive samples did harbor HPV16 DNA (range: 70 - 111
copies/genome), but not HPV18. Values for HPV-negative samples were well beneath the cutoff value (range: 0.0003 - 0.000004 copies/genome),
with the exception of three samples (2867, 2854, 2792) that were beneath the limit of detection.

practices may provide additional insights in future investigations [55,58,59,70]. Finally, screening for additional
high-risk HPV strains [71-75] and other oral infectious
agents may be possible in future studies with more significant resources and personnel.

Conclusions
This study successfully recruited patients and screened
saliva samples for high-risk HPV, confirming HPV16,
but not HPV18, was present in a small subset of the
healthy adult patients in a US dental school clinic population. These patients were female and minority. Many
health disparities face females and minorities in the US,
and with some evidence suggesting that smoking and
oropharyngeal cancer rates may be increasing in these
population subgroups, the results of this study may be
of significant value to other dental, medical, and health

care professionals to further an understanding of oral
health and disease risk.
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